# R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL

> **NCT03213977** · PHASE3 · UNKNOWN · sponsor: **Fujian Medical University** · enrollment: 475 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** R-DA-EPOCH
- **DRUG:** R-CEOP90

## Key facts

- **NCT ID:** NCT03213977
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-10
- **Primary completion:** 2023-07-13
- **Final completion:** 2024-07-13
- **Target enrollment:** 475 (ESTIMATED)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03213977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03213977, "R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03213977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*